JPMorgan analyst Tessa Romero lowered the firm’s price target on Nurix Therapeutics (NRIX) to $22 from $30 and keeps an Overweight rating on the shares following a transfer of coverage. The firm views Nurix as a “differentiated name” within the emerging oral target protein degrader space.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics Appoints Roger Dansey to Board
- Nurix Therapeutics appoints Dansey to board of directors
- Nurix Therapeutics announces presentation of new data on NX-1607
- Promising Data from Nurix Therapeutics’ Bexobrutideg Supports Buy Rating
- Nurix Therapeutics’ Bexodeg: Promising Efficacy and Safety Profile Drive Buy Rating